GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » LT-Debt-to-Total-Asset

Transition Therapeutics (Transition Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2016)


View and export this data going back to 2007. Start your Free Trial

What is Transition Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Transition Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2016 was 0.00.

Transition Therapeutics's long-term debt to total assets ratio stayed the same from Mar. 2015 (0.00) to Mar. 2016 (0.00).

Transition Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Transition Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transition Therapeutics LT-Debt-to-Total-Asset Chart

Transition Therapeutics Annual Data
Trend Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Transition Therapeutics Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Transition Therapeutics LT-Debt-to-Total-Asset Calculation

Transition Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2015 is calculated as

LT Debt to Total Assets (A: Jun. 2015 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2015 )/Total Assets (A: Jun. 2015 )
=0/40.153
=

Transition Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2016 is calculated as

LT Debt to Total Assets (Q: Mar. 2016 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2016 )/Total Assets (Q: Mar. 2016 )
=0/25.02
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transition Therapeutics  (NAS:TTHI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Transition Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Transition Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Transition Therapeutics (Transition Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
AGE ASX:MDC TSX:BU BKK:IP OPNT OHEL:HRTIS XPAR:GNRO NLNK MRNS GNCA XKRX:038070 ROCO:6696 TSXV:MPH OSTO:DMYD B CYCN XTER:CNWK TSE:4570 KZR BVXV XMAD:BIO
Traded in Other Exchanges
N/A
Address
Website
http://www.transitiontherapeutics.com
Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045